| A radioligand therapeutic agent (a radiopharmaceutical) being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of PSMA-positive metastatic prostate cancer |
| Received its first approval on 23 March 2022 in the USA |
| Approved for use in adult patients with PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.